Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8568737 | 0.93 | LTB4R (0.49) | LTB4RLTB4R2 | |
| SCHEMBL7631126 | 0.93 | LTB4R (0.49) | LTB4RLTB4R2 | |
| SCHEMBL7645606 | 0.89 | LTB4R (0.54) | LTB4RLTB4R2 | |
| SCHEMBL27570394 | 0.87 | LTB4R (0.49) | LTB4RLTB4R2 | |
| SCHEMBL8567666 | 0.82 | NR1H4 (0.40) | LTB4RLTB4R2 | |
| SCHEMBL8569026 | 0.78 | NR1H4 (0.44) | LTB4RLTB4R2 | |
| SCHEMBL7646400 | 0.73 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL7647502 | 0.73 | LTB4R (0.65) | LTB4RLTB4R2 | |
| SCHEMBL7645978 | 0.71 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL8565146 | 0.71 | CNR2 (0.39) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053962-A1 | Methods for inhibiting proliferation and inducing apoptosis in cancer cells | CREIGHTON UNIVERSITY | 2004-03-18 | — | — | US | claimed |
| EP-1326605-A4 | METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS | UNIV CREIGHTON (US) | 2004-03-17 | — | — | EP | claimed |
| EP-1326605-A1 | METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS | CREIGHTON UNIVERSITY (US) | 2003-07-16 | — | — | EP | claimed |
| CN-1390139-A | Oncolytic combinations for the treatment of cancer | LILLY CO ELI (US) | 2003-01-08 | — | — | CN | claimed |
| EP-1231939-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | claimed |
| EP-1231938-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | claimed |
| EP-0964683-A4 | LEUKOTRIENE ANTAGONISTS FOR ORAL SQUAMOUS CELL CARCINOMA | LILLY CO ELI (US) | 2002-08-14 | — | — | EP | claimed |
| EP-0961617-A4 | LEUKOTRIENE ANTAGONISTS FOR CEREBRAL FOCAL STROKE | LILLY CO ELI (US) | 2002-08-07 | — | — | EP | claimed |
| WO-2001085166-A1 | METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS | CREIGHTON UNIVERSITY (US) | 2001-11-15 | — | — | WO | claimed |
| JP-2001509142-A | — | — | 2001-07-10 | — | — | JP | claimed |
| WO-1998042334-A1 | LEUKOTRIENE ANTAGONISTS USEFUL FOR TREATING SQUAMOUS CELL CARCINOMA | ELI LILLY AND COMPANY (US) | 1998-10-01 | — | — | WO | claimed |
| WO-1998042346-A1 | LEUKOTRIENE ANTAGONISTS USEFUL FOR TREATING ISCHEMIA REPERFUSION INJURY | ELI LILLY AND COMPANY (US) | 1998-10-01 | — | — | WO | claimed |
| WO-1998025600-A1 | LEUKOTRIENE ANTAGONISTS FOR TREATMENT OR INHIBITION OF GOUT | ELI LILLY AND COMPANY (US) | 1998-06-18 | — | — | WO | claimed |
| WO-1998025616-A1 | LEUKOTRIENE ANTAGONISTS FOR CEREBRAL FOCAL STROKE | ELI LILLY AND COMPANY (US) | 1998-06-18 | — | — | WO | claimed |
| WO-1998025615-A1 | LEUKOTRIENE ANTAGONISTS FOR ORAL SQUAMOUS CELL CARCINOMA | ELI LILLY AND COMPANY (US) | 1998-06-18 | — | — | WO | claimed |
| EP-0544488-B1 | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1998-03-11 | — | — | EP | claimed |
| WO-1996036347-A1 | USE OF LEUKOTRIENE ANTAGONISTS FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-11-21 | — | — | WO | claimed |
| EP-0743064-A1 | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease | ELI LILLY AND COMPANY (US) | 1996-11-20 | — | — | EP | claimed |
| US-5462954-A | Antiinflammatory, antiallergens; treating asthma | ELI LILLY AND COMPANY (US) | 1995-10-31 | — | — | US | claimed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053962-A1 | Methods for inhibiting proliferation and inducing apoptosis in cancer cells | LTB4R, LTB4R2, ALOX5 | LTB4R 1/4885LTB4R2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.